Márcia Araújo

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Metastatic Breast Cancer

Top Venues

Oncology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy (2024)
Debora de Melo Gagliato, Tomás Reinert, Cláudio Rocha, Monique Celeste Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Ferreira Cardoso, Vivienne Carduz Castilho
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncology and therapy 12 (3) (2024)